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Aims/hypothesis: We investigated whether urinary markers of nucleic acid oxidation are associated with
an increased risk of cancer in type 2 diabetes patients.
Methods: Urine samples from 1381 newly diagnosed diabetes patients were assayed for the oxidatively
modiﬁed guanine nucleosides 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) and 8-oxo-7,8-dihy-
droguanosine (8-oxoGuo). Cox proportional hazards regression was used to examine the relationship
between the urinary markers and cancer incidence.
Results: The crude analyses showed an association between overall cancer and urinary excretion of the
RNA oxidation marker 8-oxoGuo (unadjusted hazard ratio for cancer per natural log increase in 8-oxoGuo
1.35 [95% CI, 1.01–1.81]), however, in the adjusted analyses, no signiﬁcant associations between 8-oxodG
or 8-oxoGuo and overall cancer were found. For site-speciﬁc cancers 8-oxodG was associated with breast
cancer in the crude analyses (unadjusted hazard ratio for breast cancer per natural log increase in
8-oxodG was 2.37 [95% CI, 1.07–5.26]), although the association was attenuated in the adjusted analyses
(sex- and age-adjusted hazard ratio 2.15 [95% CI, 0.92–5.02] and multivariate adjusted hazard ratio1.98
[95% CI, 0.95–4.10]).
Conclusions: Urinary excretion of the nucleic acid oxidation markers 8-oxodG and 8-oxoGuo at the time
of diagnosis was not associated with cancer overall in type 2 diabetes patients. For site-speciﬁc cancers,
risk elevations were seen for breast cancer (8-oxodG). These ﬁndings should be examined in future and
larger studies.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Epidemiological studies suggest that type 2 diabetes is asso-
ciated with increased risks of several cancer types, including
cancers of the liver, pancreas, breast, endometrium, kidney, blad-
der, and colorectum [1–4]. Although diabetes may inﬂuence car-
cinogenesis by several mechanisms, e.g., hyperinsulinaemia, hy-
perglycaemia, or chronic inﬂammation, any exact mechanisms
underlying the association between type 2 diabetes and cancer
remain to be established. The mutagenic properties of oxidatively
damaged DNA and the fact that diabetes is associated with in-
creased urinary excretion of the DNA oxidation marker 8-oxo-7,8-
dihydro-2′-deoxyguanosine (8-oxodG) [5] suggest that DNA oxi-
dation could be one possible biological link between diabetes and
cancer risk, and that urinary 8-oxodG may predict development of
cancer in diabetes patients.
No previous studies have explored the relationship between
8-oxodG excretion and cancer incidence in type 2 diabetes pa-
tients. In general, the evidence on a potential association between
urinary 8-oxodG excretion and cancer is limited, although some
studies have demonstrated elevated levels of urinary 8-oxodG in
patients with various malignancies [6–13]. We recently showed
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that urinary excretion of 8-oxo-7,8-dihydroguanosine (8-oxoGuo),
the ribonucleoside counterpart to 8-oxodG, is an independent
predictor of mortality in type 2 diabetes patients [14,15]. Whether
8-oxoGuo is also associated with cancer incidence is unknown.
In this study, we investigated whether urinary markers of
oxidative stress 8-oxodG and 8-oxoGuo are associated with an
increased risk of cancer in type 2 diabetes patients.
Methods
Study population
In the Diabetes Care in General Practice (DCGP) study [16], 474
general practitioners agreed to include all subjects on their prac-
tice list who fulﬁlled the following criteria: newly diagnosed dia-
betes based on hyperglycaemic symptoms and/or raised blood
glucose values, diagnosed between 1 March 1989 and 28 February
1992, and aged 40 years or over. The diabetes diagnosis was sub-
sequently conﬁrmed with a single fasting whole blood/plasma
glucose value of Z7.0/8.0 mmol/l, measured in a major laboratory.
The protocol-based exclusion criteria were life threatening somatic
disease, severe mental illness, or unwillingness to participate.
After exclusion of 162 patients, the study population consisted of
1381 newly diagnosed diabetes patients. Based on the onset of
insulin treatment within 180 days of diagnosis, approximately
97.5% were considered to have type 2 diabetes [16]. Freshly voided
morning urine samples were collected from all patients at the time
of diagnosis.
The protocol was approved by the ethics committee of Co-
penhagen and Frederiksberg and informed consent was obtained
from all patients.
Assessment of urinary markers and covariates
The urine samples were assayed between 2009 and 2010 for
the oxidatively modiﬁed guanine nucleosides 8-oxodG and 8-ox-
oGuo using a validated method of ultraperformance liquid chro-
matography (UPLC) and tandem mass spectrometry [17]. 8-oxodG
and 8-oxoGuo were normalized against urinary creatinine con-
centration. The assessment of the remaining patient character-
istics at baseline has been described elsewhere [16].
Ascertainment of cancer
Information on cancer incidence was obtained from the Danish
Cancer Registry [18], which contains accurate and virtually com-
plete records of cancer cases in Denmark. The patients were fol-
lowed for cancer occurrence from date of diabetes diagnosis until
1 January 2009.
Statistical analysis
The patients were grouped according to the quartiles of their
urinary 8-oxodG and 8-oxoGuo levels in order to examine the
associations between patient characteristics at diagnosis and the
corresponding levels of oxidative stress. The medians and inter-
quartile ranges (for continuous characteristics) or percentages (for
categorical characteristics) were reported for each quartile, and
associations were assessed by Kruskal–Wallis or chi-square tests,
respectively.
Associations between oxidative stress and cancer risk were
estimated by Cox proportional hazards regression models based
on time from diagnosis to cancer event or censoring. Oxidative
stress was represented by the natural logarithm of 8-oxodG and
8-oxoGuo, and by a four-class ordinal variable corresponding to
the quartiles of the distribution. Three models were estimated for
each of the oxidative stress variables and each outcome: an un-
adjusted model, a model adjusted for age and sex, and a third
model adjusting for sex, age, smoking status, physical activity,
education, BMI, alcohol consumption and cohabitation status.
We restricted cancer site-speciﬁc analyses to the most common
cancer types in the cohort (more than 20 events). In these ana-
lyses, the above-mentioned models were used, and oxidative
stress was represented by the natural logarithm of 8-oxodG and
8-oxoGuo.
Cancer incidence was plotted against follow-up time using the
Kaplan–Meier method.
Reported p values were two-sided and po0.05 was considered
to be signiﬁcant. Analyses were performed with SAS version 9.2.
Results
Patient characteristics
The median age at diagnosis of diabetes was 65.4 years (in-
terquartile range, 55.7–73.6 years), with a slight male pre-
ponderance (53%). Tables 1 and 2 show the baseline characteristics
according to quartiles of 8-oxodG and 8-oxoGuo, respectively. For
both 8-oxodG and 8-oxoGuo, patients in the highest quartiles were
older, more often women, more often living alone, and had higher
levels of glycated haemoglobin. In addition, patients in the highest
quartiles of 8-oxodG had lower BMI, total cholesterol and serum
creatinine, and patients in the highest quartiles of 8-oxoGuo were
more often highly educated, less often smokers, and less physically
active.
Nucleic acid oxidation and overall cancer risk
We identiﬁed a total of 264 incident cancers during follow-up.
Kaplan–Meier estimates of cancer incidence for all subjects ac-
cording to quartiles of urinary 8-oxodG and 8-oxoGuo are shown
in Fig. 1.
In the unadjusted Cox regression analyses, log8-oxoGuo was
signiﬁcantly associated with cancer (Table 3). The unadjusted ha-
zard ratio for cancer per natural log increase in 8-oxoGuo was 1.35
(95% conﬁdence interval [CI], 1.01–1.81; p¼0.04). In the adjusted
analyses, no signiﬁcant associations between 8-oxodG or 8-ox-
oGuo and overall cancer were found. Both analyses using the
quartiles of distribution and log8-oxodG and log8-oxoGuo as
continuous covariates showed no association between urinary
excretion of the two markers and risk of cancer.
Risk of site-speciﬁc cancers
For both 8-oxodG and 8-oxoGuo, the site-speciﬁc hazard ratios
varied in direction and magnitude (Table 4), probably due to the
small numbers of cancer cases. Elevated risk estimates were ob-
served for breast cancer. The unadjusted hazard ratio for breast
cancer per natural log increase in 8-oxodG was 2.37 (95% CI, 1.07–
5.26; p¼0.03). When adjusting for covariates in models 2 and 3,
the corresponding hazard ratios were 2.15 (95% CI, 0.92–5.02;
p¼0.08) and 1.98 (95% CI, 0.95–4.10; p¼0.07), respectively.
Discussion
This cohort study that included 1381 newly diagnosed type
2 diabetes patients observed for up to 20 years is the ﬁrst pro-
spective study to explore the association between urinary excre-
tion of markers of oxidative stress and cancer in diabetes patients.
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Table 1
Baseline characteristics according to quartiles of 8-oxodG.
Characteristic 1st quartile
(N¼338)
2nd quartile
(N¼338)
3rd quartile
(N¼338)
4th quartile
(N¼338)
p Valuen
8-oxodG (nmol/mmol creatinine) o1.60 1.60–2.09 2.10–2.77 42.77
Male sex (%) 62.4 53.0 53.6 44.1 o0.001
Age (yr) 62.1 (54.2–70.1) 65.6 (54.5–73.5) 64.7 (54.8–72.3) 69.4 (59.4–75.7) o0.001
Smoking status (%) 0.06
Never 26.0 30.2 28.6 37.0
Previous 36.4 37.5 34.7 30.7
Current 37.6 32.3 36.8 32.2
Physical activity (%) 0.09
Low 27.1 25.4 26.3 32.3
Moderate 66.9 66.7 65.9 64.4
High 6.1 8.0 7.9 3.3
Cohabitation status (living alone) (%) 27.4 30.3 29.6 41.0 o0.001
Education (higher) (%) 76.2 79.6 79.8 80.6 0.52
Glycated haemoglobin (%) 9.9 (8.3–11.2) 9.8 (8.4–11.7) 10.3 (8.9–11.9) 10.7 (9.1–12.2) o0.001
Total cholesterol (mmol/l) 6.5 (5.6–7.4) 6.2 (5.4–7.0) 6.2 (5.4–7.1) 6.0 (5.2–6.9) 0.001
Fasting triglycerides (mmol/l) 2.28 (1.44–3.38) 1.89 (1.41–2.66) 2.05 (1.38–2.93) 1.87 (1.37–2.65) 0.05
Serum creatinine (mmol/l) 90.0 (83.0–103.0) 90.0 (80.0–101.0) 89.0 (79.0–99.0) 87.0 (78.5–99.0) 0.03
Urinary albumin (mg/l) 10.4 (5.3–25.5) 10.8 (5.5–23.9) 11.2 (6.2–29.1) 15.5 (6.9–35.9) 0.63
Hypertension (%)† 76.0 74.3 74.0 73.4 0.87
BMI (kg/m2) 29.7 (26.7–33.2) 29.7 (26.4–33.6) 29.0 (26.0–32.4) 28.3 (24.9–31.2) o0.001
Retinopathy (%) 3.3 4.7 5.0 4.9 0.75
Peripheral neuropathy (%) 17.2 20.5 18.9 20.4 0.66
History of acute myocardial infarction (%) 10.4 8.6 7.7 7.1 0.45
History of stroke (%) 5.3 3.0 4.1 5.0 0.44
Medians (interquartile ranges) are shown.
n p Values are from chi-square tests (for categorical data) or from analysis of variance (for continuous data).
† Hypertension was deﬁned as systolic/diastolic blood pressure Z160/90 mmHg or the use of antihypertensive drugs.
Table 2
Baseline characteristics according to quartiles of 8-oxoGuo.
Characteristic 1st quartile
(N¼336)
2nd quartile
(N¼337)
3rd quartile
(N¼337)
4th quartile
(N¼337)
p Valuen
8-oxoGuo (nmol/mmol creatinine) o2.86 2.86–3.63 3.64–4.77 44.77
Male sex (%) 64.9 59.6 46.6 41.5 o0.001
Age (yr) 60.8 (51.3–69.1) 62.0 (53.6–70.1) 66.8 (58.6–74.5) 70.2 (61.9–76.6) o0.001
Smoking status (%) 0.02
Never 25.2 29.7 28.8 38.3
Previous 36.5 33.6 37.7 31.3
Current 38.3 36.7 33.4 30.4
Physical activity (%) o0.001
Low 21.3 24.8 26.3 38.9
Moderate 68.7 67.2 70.0 58.1
High 10.0 8.0 3.7 3.0
Cohabitation status (living alone) (%) 25.8 20.3 33.0 42.8 o0.001
Education (higher) (%) 70.9 79.7 79.3 86.4 o0.001
Glycated haemoglobin (%) 9.7 (8.3–11.0) 9.8 (8.5–11.4) 10.4 (8.8–12.0) 11.0 (9.1–12.4) o0.001
Total cholesterol (mmol/l) 6.2 (5.4–7.1) 6.2 (5.5–7.1) 6.2 (5.4–7.1) 6.2 (5.3–7.2) 0.99
Fasting triglycerides (mmol/l) 1.96 (1.30–2.86) 1.94 (1.34–2.89) 1.99 (1.47–2.83) 2.02 (1.49–2.93) 0.32
Serum creatinine (mmol/l) 90.0 (82.0–101.0) 90.0 (80.0–100.0) 88.0 (79.0–101.0) 89.0 (79.0–102.0) 0.21
Urinary albumin (mg/l) 10.0 (5.4–21.2) 11.6 (5.5–23.7) 11.5 (6.3–29.5) 15.5 (7.0–42.2) 0.21
Hypertension (%)† 73.5 69.7 77.4 77.4 0.06
BMI (kg/m2) 29.1 (26.2–32.2) 29.4 (26.6–32.9) 29.4 (26.4–33.1) 28.7 (25.1–32.6) 0.24
Retinopathy (%) 4.1 4.7 2.6 6.5 0.14
Peripheral neuropathy (%) 15.0 16.3 21.3 24.0 0.009
History of acute myocardial infarction (%) 9.0 7.1 7.5 10.4 0.40
History of stroke (%) 3.6 4.5 4.5 5.0 0.83
Medians (interquartile ranges) are shown.
n p Values are from chi-square tests (for categorical data) or from analysis of variance (for continuous data).
† Hypertension was deﬁned as systolic/diastolic blood pressure Z160/90 mmHg or the use of antihypertensive drugs.
K. Broedbaek et al. / Redox Biology 4 (2015) 34–3936
We found an apparent association with urinary excretion of the
RNA oxidation marker 8-oxoGuo in the crude analyses, however,
this disappeared in the adjusted analyses. In none of the analyses,
excretion of 8-oxodG was associated with cancer overall. For site-
speciﬁc cancer, elevated risk estimates were seen for some sites,
however, a consistent pattern over the varying levels of con-
founder adjustment was only seen for breast cancer and excretion
of 8-oxodG. However, the statistical precision of notably the site
speciﬁc analyses was limited and small to moderate associations
between the nucleic acid markers and cancer could have been
missed. Hence, the analyses should be repeated in other larger
studies.
In two nested case–control/case–cohort studies within a large
population-based prospective cohort study, Loft et al. examined
associations between urinary excretion of 8-oxodG and risk of lung
cancer [19] and breast cancer [20], respectively. In the ﬁrst study
260 cases with lung cancer and a sub-cohort of 263 individuals
matched on sex, age and smoking duration were included. In ac-
cordance with our ﬁndings Loft et al. found that overall the ex-
cretion of 8-oxodG was not signiﬁcantly associated with the risk of
lung cancer [19]. However, among never-smokers a high excretion
of 8-oxodG was signiﬁcantly associated with an increased risk of
developing lung cancer [19]. Interestingly, the results from the
other study by Loft et al. [20] are also in accordance with our
ﬁndings regarding breast cancer incidence in type 2 diabetes pa-
tients. Loft et al. included 336 matched case–control pairs and
found a borderline signiﬁcant positive association between 8-ox-
odG and risk of all breast cancer (IRR: 1.08; 95% CI 1.00–1.17 per
unit increase in nmol/mmol creatinine), which was signiﬁcant
with respect to the risk of oestrogen receptor-positive cancers
(IRR: 1.11; 95% CI 1.01–1.23) and among women with low dietary
iron intake (IRR: 1.10; 95% CI 1.06–1.37) [20]. Future studies are
needed to conﬁrm this apparent association between urinary
8-oxodG excretion and breast cancer.
The mechanistic evidence for the mutagenic effects of DNA
oxidation by modiﬁcation has been well established [21–24].
However, our data combined with the other epidemiological evi-
dence indicate that from a clinical point of view the contributing
effect of oxidative DNA modiﬁcations to human carcinogenesis is
modest.
The main strengths of our study include the long follow-up
period, the low attrition rate, the measurement of 8-oxodG and
Fig. 1. Kaplan–Meier estimates of cancer incidence for all subjects according to quartiles of urinary 8-oxodG and 8-oxoGuo.
Table 3
Association of urinary 8-oxodG and 8-oxoGuo with overall cancer risk.
Outcome Model 1
HR (95% CI)
p Value Model 2
HR (95% CI)
p Value Model 3
HR (95% CI)
p Value
Any cancer (n¼264)
8-oxodG 0.25n 0.74n 0.98n
1st quartile 1.00 1.00 1.00
2nd quartile 0.92 (0.63–1.32) 0.63 0.85 (0.59–1.24) 0.40 0.85 (0.58–1.24) 0.40
3rd quartile 0.97 (0.69–1.36) 0.87 0.88 (0.62–1.25) 0.48 0.88 (0.62–1.25) 0.46
4th quartile 1.22 (0.85–1.74) 0.27 1.05 (0.73–1.52) 0.79 1.00 (0.69–1.46) 0.99
Log 8-oxodG 1.13 (0.82–1.54) 0.46 1.00 (0.72–1.38) 0.99 0.94 (0.68–1.29) 0.68
8-oxoGuo 0.06n 0.64n 0.91n
1st quartile 1.00 1.00 1.00
2nd quartile 1.15 (0.82–1.61) 0.41 1.07 (0.76–1.50) 0.72 0.97 (0.68–1.37) 0.85
3rd quartile 1.25 (0.90–1.74) 0.18 1.00 (0.70–1.43) 0.99 0.96 (0.67–1.37) 0.82
4th quartile 1.39 (0.98–1.98) 0.07 1.13 (0.77–1.64) 0.53 0.98 (0.67–1.44) 0.92
Log 8-oxoGuo 1.35 (1.01–1.81) 0.04 1.08 (0.79–1.49) 0.63 0.98 (0.71–1.37) 0.93
Model 1: unadjusted model. Model 2: adjusted for age and sex. Model 3: adjusted for sex, age, smoking status, physical activity, education, BMI, alcohol consumption and
cohabitation status.
n p Value for linear trend across quartiles.
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8-oxoGuo with a validated method of UPLC and tandem mass
spectrometry, the high quality in cancer diagnoses from the Dan-
ish Cancer Registry, and the availability of important potential
clinical confounders.
The main limitation of our study was the sample size. Despite a
total number of 264 cancer events, the statistical precision was
low, limiting our ability to detect small and moderate associations
between the oxidative stress markers and cancer risk, notably for
site-speciﬁc cancers. This means that if the nucleic acid oxidation
markers actually are associated with increased risk of cancer, this
risk is too small to be detected in this study. Another limitation of
this study was the reliance on a single measurement of the nucleic
acid oxidation markers in a morning spot urine sample at the time
of diagnosis. Thus the markers only reﬂect the oxidative burden at
this speciﬁc time point. The possibility exists that the risk of cancer
is associated with the accumulated oxidative burden during the
follow-up period, which again could depend on the glycaemic
regulation in the patients in this period.
In summary, urinary excretion of the nucleic acid oxidation
markers 8-oxodG and 8-oxoGuo at the time of diagnosis was not
associated with cancer overall in our large cohort of type 2 dia-
betes patients. For site-speciﬁc cancers, risk elevations were seen
for breast cancer (8-oxodG). However, these ﬁndings should be
examined in future and larger studies.
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